This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Power calculations to determine the sample size were not reported. All eligible patients in the study period whose surnames began with the letters A to K were included in the study group. Those patients whose surnames began with the letters L to Z were included in the control group. The number of patients or interventions included in the analysis depended on the type of analysis performed. Three types of analysis of effectiveness were performed. Analysis A included only inpatients with interventions. There were 24 patients or interventions in the control group and 52 patients or interventions in the study group. Analysis B included all patients with matching diagnosis-related group (DRG), independently of whether they had had an intervention. There were 190 patients in the control group and 188 in the study group. Analysis C included DRG-matched patients, as in analysis B, but adjusted for severity. Consequently, the sample was the same as in analysis B.
Study design
Initially, the design of this single-centre study was quasi-randomised, since the patients were allocated to the control and study groups on the basis of the first letters of their surname. The length of follow-up was not reported, but it appears that the patients were followed for at least 4 days.
Analysis of effectiveness
The basis of the clinical analysis (intention to treat or treatment completers only) was not stated. The primary health outcomes used in the analysis were the number of interventions performed, the mortality rate and the mean length of stay in hospital.
In analysis A, there was a non significant difference in the average age of the study group (64.7 years) and control group (67.3 years). There was also a non significant difference in the Health Care Financing Administration (HCFA) weights for the DRG categories, which were 2.4 in the study group and 5.4 in the control group.
In analysis B, the average age was 66.1 years in the study group and 65.6 years in the control group. The HCFA weights were 2.2 in the study group and 2.5 in the control group. The different numbers of patients in the different DRGs in the study and control groups were adjusted to improve the comparability of the two groups.
Effectiveness results
The number of interventions was 52 (79% were accepted) in the study group and 24 (71% were accepted) in the control group. In analyses A and B, the mortality rate did not differ significantly between the study and control groups. In analysis A, the mortality rate was 7.7% in the study group and 12.5% in the control group, (p=0.68). In analysis B, the mortality rate was 11.2% in the study group and 10.0% in the control group, (p=0.741). In analysis C, the severityadjusted mortality rate was 12.6% in the control group and 11.2% in the study group. This represented a decrease in the mortality rate of 1.4% in the study group.
In analysis A, the average length of stay in the hospital was 16.5 days per patient in the study group and 33 days per patient in the control group. The difference was 16.5 days, (p=0.37). In analysis B, the average length of stay in the hospital was 11 days per patient in the study group and 13.7 days per patient in the control group. The difference was 2.7 days (p=0.035). In analysis C, the control group had a severity-adjusted length of stay of 12.2 days in the hospital. This represented a decrease of 1.2 days per patient in the average length of stay for the study group.
Clinical conclusions
The difference in mortality rates between the study and control groups was insignificant in all of the analyses. Only analysis B showed an unfavourable mortality rate for the study group. However, this difference was small and insignificant, and was likely to be due to chance alone.
Measure of benefits used in the economic analysis
No summary measure of benefits was used in the economic analysis. Therefore, the benefits are associated with the effectiveness results. The costs were analysed separately for the study and the control groups. The cost-effectiveness
